Alex Dmitrienko
Overview
Explore the profile of Alex Dmitrienko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
660
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lipkovich I, Svensson D, Ratitch B, Dmitrienko A
Stat Med
. 2024 Jul;
43(22):4388-4436.
PMID: 39054669
In this paper, we review recent advances in statistical methods for the evaluation of the heterogeneity of treatment effects (HTE), including subgroup identification and estimation of individualized treatment regimens, from...
2.
Lipkovich I, Svensson D, Ratitch B, Dmitrienko A
Clin Trials
. 2023 May;
20(4):380-393.
PMID: 37203150
There has been much interest in the evaluation of heterogeneous treatment effects (HTE) and multiple statistical methods have emerged under the heading of personalized/precision medicine combining ideas from hypothesis testing,...
3.
Greenberg S, Dmitrienko A, Hayes M
Neurology
. 2022 Aug;
99(9):361-362.
PMID: 36038280
No abstract available.
4.
Johnston S, Lipkovich I, Dmitrienko A, Zhao Y
Pharm Stat
. 2022 Mar;
21(5):1090-1108.
PMID: 35322520
In this paper, we consider randomized controlled clinical trials comparing two treatments in efficacy assessment using a time to event outcome. We assume a relatively small number of candidate biomarkers...
5.
Bunouf P, Groc M, Dmitrienko A, Lipkovich I
Ther Innov Regul Sci
. 2021 Jul;
56(1):65-75.
PMID: 34327673
Data-driven subgroup analysis plays an important role in clinical trials. This paper focuses on practical considerations in post-hoc subgroup investigations in the context of confirmatory clinical trials. The analysis is...
6.
OConnell T, Bradley C, Abbas A, Williamson B, Rusia A, Tawney A, et al.
JACC Clin Electrophysiol
. 2021 Jan;
7(1):16-25.
PMID: 33478708
Objectives: This study aimed to characterize corrected QT (QTc) prolongation in a cohort of hospitalized patients with coronavirus disease-2019 (COVID-19) who were treated with hydroxychloroquine and azithromycin (HCQ/AZM). Background: HCQ/AZM...
7.
Muysers C, Dmitrienko A, Kulmann H, Kirsch B, Lippert S, Schmelter T, et al.
Ther Innov Regul Sci
. 2020 Dec;
54(3):507-518.
PMID: 33301136
Background: The analysis of subgroups in clinical trials is essential to assess differences in treatment effects for distinct patient clusters, that is, to detect patients with greater treatment benefit or...
8.
Graf A, Magirr D, Dmitrienko A, Posch M
Stat Methods Med Res
. 2020 Apr;
29(10):2945-2957.
PMID: 32223528
An important step in the development of targeted therapies is the identification and confirmation of sub-populations where the treatment has a positive treatment effect compared to a control. These sub-populations...
9.
Muysers C, Dmitrienko A, Kulmann H, Kirsch B, Lippert S, Schmelter T, et al.
Ther Innov Regul Sci
. 2019 Jun;
:2168479019853782.
PMID: 31204501
Background: The analysis of subgroups in clinical trials is essential to assess differences in treatment effects for distinct patient clusters, that is, to detect patients with greater treatment benefit or...
10.
Friede T, Posch M, Zohar S, Alberti C, Benda N, Comets E, et al.
Orphanet J Rare Dis
. 2018 Oct;
13(1):186.
PMID: 30359266
Where there are a limited number of patients, such as in a rare disease, clinical trials in these small populations present several challenges, including statistical issues. This led to an...